These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Validation--how much can the world afford? Are we getting value for money? Anisfeld MH J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419 [TBL] [Abstract][Full Text] [Related]
5. [What is the cost of drug quality?]. Hannse H Fortschr Med; 1975 Aug; 93(24):1083-4, 1112-3. PubMed ID: 818000 [No Abstract] [Full Text] [Related]
8. Pharmacoeconomics of adverse drug reactions. Lundkvist J; Jönsson B Fundam Clin Pharmacol; 2004 Jun; 18(3):275-80. PubMed ID: 15147278 [TBL] [Abstract][Full Text] [Related]
9. THE ECONOMICS OF ADVERSE DRUG REACTIONS--case studies. Visconti JA; Smith MC Ann Pharmacother; 2006 Mar; 40(3):529-36. PubMed ID: 16507611 [No Abstract] [Full Text] [Related]
10. Pharmacoeconomics. Ahuja J; Gupta M; Gupta AK; Kohli K Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600 [TBL] [Abstract][Full Text] [Related]
11. [Drug economics--a potent cure, but with the risk of adverse effects]. Kristiansen IS Tidsskr Nor Laegeforen; 1994 Mar; 114(8):901-2. PubMed ID: 8191463 [No Abstract] [Full Text] [Related]
12. Pharmaceutical research: cost savings through innovation. Cohen KR; Levy RA AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463 [No Abstract] [Full Text] [Related]
13. [Pharmacoeconomics. A new concept of an old practice]. Palma-Aguirre JA Gac Med Mex; 1998; 134(5):621-4. PubMed ID: 9842147 [No Abstract] [Full Text] [Related]
14. Achieving a quality drug supply. Nelson G J Am Pharm Assoc; 1974 Oct; 14(10):548-9, 564. PubMed ID: 4420394 [No Abstract] [Full Text] [Related]
15. [Clinical application of drugs with emphasis on more efficacy and lower costs]. Xie H; Zhou H Zhonghua Yi Xue Za Zhi; 1995 Jan; 75(1):3-4. PubMed ID: 7600317 [No Abstract] [Full Text] [Related]
16. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related]
17. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression. Zaric GS Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544 [TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic evaluations of antifungal therapies. Hennen CR Curr Med Res Opin; 2009 Jul; 25(7):1751-8. PubMed ID: 19557894 [TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics and macular degeneration. Brown GC; Brown MM; Brown H; Godshalk AN Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427 [TBL] [Abstract][Full Text] [Related]
20. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective]. Lundin D; Carlsson P; Levin LA; Persson U Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321 [No Abstract] [Full Text] [Related] [Next] [New Search]